Novel Diagnostic Biomarkers of Prostate Cancer: An Update
| Autor: | T. Tony Cai, Giuseppe Simone, Pier Mario Biava, Manuela Costantini, Davide Marsiliani, Umberto Anceschi, Franco Lugnani, Daniele Mattevi, Lorenzo G. Luciani, Gabriele Tuderti, Gianni Malossini, Alessio Filianoti, Leonardo Misuraca |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
PCA3
Oncology Male medicine.medical_specialty biomarkers diagnosis prognosis prostate cancer serum urine 030232 urology & nephrology MEDLINE Biochemistry 03 medical and health sciences Prostate cancer 0302 clinical medicine Prostate Antigens Neoplasm Internal medicine Drug Discovery medicine Biomarkers Tumor Humans Clinical significance Prospective Studies Grading (tumors) Pharmacology business.industry Organic Chemistry Prostatic Neoplasms Prostate-Specific Antigen medicine.disease Prostate-specific antigen Systematic review medicine.anatomical_structure 030220 oncology & carcinogenesis Molecular Medicine business |
| Zdroj: | Current medicinal chemistry. 26(6) |
| ISSN: | 1875-533X |
| Popis: | Objective:In recent years, several biomarkers alternative to standard prostate specific antigen (PSA) for prostate cancer (PCa) diagnosis have become available. The aim of this systematic review is to assess the current knowledge about alternative serum and urinary biomarkers for the diagnosis of PCa.Material and Methods:A research was conducted in Medline, restricted to English language articles published between December 2014 and June 2018 with the aim to update previously published series on PCa biomarkers. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria were used for selecting studies with the lowest risk of bias.Results:Emerging role and actual controversies on serum and urine alternative biomarkers to standard PSA for PCa diagnosis, staging and prognosis assessment, such as prostate health index (PHI), PCA3, ConfirmMDx, Aberrant PSA glycosylation, MiPS, miRNAs are critically presented in the current review.Conclusion:Although the use of several biomarkers has been recommended or questioned by different international guidelines, larger prospective randomized studies are still necessary to validate their efficacy in PCa detection, discrimination, prognosis and treatment effectiveness. To date, only PHI and 4Kscore have shown clinical relevance for discriminating more aggressive PCa. Furthermore, a new grading classification based on molecular features relevant for PCa risk-stratification and tailoring treatment is still needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|